Mirati Therapeutics Inc
MRTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.12B
Close$
$66.66
13.6% upside
Current Fair Value
13.6% upsideUndervalued by 13.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.12 Billion |
|---|---|
| Enterprise Value | $3.90 Billion |
| Earnings per Share | $-13.18 |
| Beta | 0.77 |
| Outstanding Shares | 64,993,000 |
Return
| Return on Equity | -75.72% |
|---|---|
| Return on Assets | -63.44% |
| Return on Invested Capital | -77.30% |
Valuation & Multiples
| P/E Ratio | -4.45 |
|---|---|
| PEG | 66.31 |
| Price to Sales | - |
| Price to Book Ratio | 4.19 |
| Enterprise Value to Revenue | 102.15 |
| Enterprise Value to EBIT | -5.09 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Mirati Therapeutics Inc
CEO: Charles Baum
